EN DE
Watch Opko Health Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Opko Health Inc (OPK) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Opko Health Inc stock $1.54, price $1.62, that is 4.9% below the price, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US68375N1037

OH Opko Health Inc logo Thin data Nov 17, 2026

Opko Health Inc

OPK · US

Rising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Fair value $1.54 · Fairly valued 
Insiders sold $24,577 (6M) 
Quality 38/100 
Weak Growth (revenue 5y −15.8 %/yr in USD) 
Loss-making · -12.4% net margin (TTM) 
Negative free cash flow 
Trails peers (3/11) 
Narrow moat 12/100
Thin data 
Estimate
Watch Opko Health Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.15 $0.8655 Fair Value $1.54 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.8655 – $5.15 · fair‑value band $1.15 – $1.92 · the $1.62 price screens above the $1.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Opko Health in your weekly email

Every Wednesday you see whether Opko Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.

Show moreShow less

The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system.

This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency.

The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test.

OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Stock analysis

Opko Health Inc (OPK) currently trades at $1.62, while our estimate is $1.54, so the stock looks roughly fairly valued today (gap 5.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.15 (bear) to $1.92 (bull), the price of $1.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Opko Health Inc reported revenue of $607M in FY2025 versus $1.8B in FY2021, a compound −23.5%/yr. Reported net income was −$226M in FY2025.

Key figures

Market cap $1.2B Small · P/S ratio 2.18 · EPS (TTM) $−0.1600 · Net margin −37.2% · Return on equity −5.9% · Return on assets (EBIT) −7.1% (5-year average) · Operating margin −15.3% · Revenue (TTM) $588M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 8% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −5%, OPK screens cheaper than that median.

Fair Value

Bear $1.15 Fair Value $1.54 Bull $1.92
Price $1.62 · Downside -4.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 16
How calm the share price moves, does not count
Price momentum 74
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $24,577 and none bought.

  • SaleJohn A PaganelliDirector13,601 shares at $1.81$24,577Nov 5, 2026
  • BuyJohn A PaganelliDirector10,000 shares at $1.14$11,400Mar 20, 2026
  • BuyFrost Gamma Investments Trust10% owner4× since Nov 18, 2025: 2,273,300 shares, avg. $1.31$3.0MNov 21, 2025

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.8%
Start year 2020 (pandemic). Over 10 years: +2.1% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.0% (2020) → −36.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch OPK, get fair value alerts →

Compare Opko Health Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −4.9% · Above median
Profitability
Return on assets −11.7% · Bottom 25%
Net margin (12 months) −12.4% · Below median
Operating margin (12 months) −15.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 4.3% · Below median
Balance sheet
Debt / equity 0.26× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.96× · Cheapest 25%
P/S (12 months) 2.08× · Cheaper than median
PEG 93.65× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 19
FUTURE (revenue growth)22 · sector 40
PAST (return on equity)0 · sector 9
HEALTH (low debt)87 · sector 95
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $198.00 $227.71 +15% vs OPK
WuXi AppTec Co 603259 ¥144.41 ¥164.66 +14% vs OPK
IQVIA Holdings IQV $264.73 $291.63 +10% vs OPK
Thermo Fisher Scientific Inc TMO $691.33 $686.04 −1% vs OPK
Danaher Corporation DHR $229.91 $209.18 −9% vs OPK
IDEXX Laboratories, Inc IDXX $700.65 $496.48 −29% vs OPK
Lonza Group LONN CHF 670.20 CHF 259.80 −61% vs OPK
Mettler-Toledo International Inc MTD $1,727 $655.06 −62% vs OPK
Agilent Technologies, Inc A $172.92 $64.20 −63% vs OPK
Waters Corporation WAT $453.42 $91.26 −80% vs OPK

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Opko Health Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Opko Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/OPK

Frequently asked questions

Is Opko Health Inc (OPK) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $1.54 versus a price of $1.62, about 5% lower (fairly valued).
What is the fair value of OPK?
Our estimate for Opko Health Inc is $1.54 (as of Nov 17, 2026), built from audited fundamentals. The current price: $1.62.
What is the quality score of OPK?
Opko Health Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Opko Health Inc (OPK)?
Our calculated price target is the estimate of $1.54 (as of Nov 17, 2026). Cautious scenario $1.15, optimistic scenario $1.92. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Opko Health Inc stock forecast for 2026?
Our estimate puts fair value at $1.54, about 5% lower versus a price of $1.62 (fairly valued). Cautious scenario $1.15, optimistic scenario $1.92. The calculation is refreshed regularly with new filings.
What is the revenue of Opko Health Inc (OPK)?
Opko Health Inc reported trailing-twelve-month revenue of about $588M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Opko Health Inc (OPK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Opko Health Inc it is $1.54 per share (as of Nov 17, 2026), against a price of $1.62.
Is Opko Health Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, OPK trades above its calculated fair value: price $1.62, fair value $1.54, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPK?
No. The price is what the market pays today ($1.62); the fair value is what the company's own numbers justify ($1.54). For Opko Health Inc the two are $0.0800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Opko Health Inc worth?
The market values Opko Health Inc at about $1.2B (market capitalisation, as of Nov 17, 2026). Per share that is $1.62; our models calculate a fair value of $1.54 per share.
What do the bullish and bearish scenarios say about OPK?
Our models span a range for Opko Health Inc: cautious scenario $1.15, base $1.54, optimistic $1.92 per share (as of Nov 17, 2026, price $1.62). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of OPK?
The PEG ratio of Opko Health Inc is 93.65 (P/E divided by earnings growth, as of Nov 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Opko Health Inc (OPK)?
Balance-sheet figures for Opko Health Inc (as of Nov 17, 2026): return on equity −5.9%, debt of 0.26 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is OPK from its 52-week high?
Opko Health Inc trades at $1.62, about 8% below its 52-week high of $1.77 and 47% above the low of $1.10 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.54 is for.
Which stocks are comparable to Opko Health Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Opko Health Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $1.62, calculated fair value $1.54 (−5%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Opko Health Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Opko Health Inc (OPK)?
The closing price on Nov 16, 2026 was $1.62. Our estimate is $1.54, about 5% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Opko Health Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Opko Health Inc

How large is the market capitalisation of Opko Health Inc (OPK)?
The market capitalisation of Opko Health Inc is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Opko Health Inc (OPK)?
The price-to-sales ratio of Opko Health Inc is 2.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Opko Health Inc (OPK)?
Earnings per share at Opko Health Inc are $−0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Opko Health Inc (OPK)?
The net margin of Opko Health Inc is −37.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Opko Health Inc (OPK)?
The return on equity (ROE) of Opko Health Inc is −5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Opko Health Inc (OPK)?
On an EBIT basis the return on assets of Opko Health Inc is −7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Opko Health Inc (OPK)?
The operating margin of Opko Health Inc is −15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Opko Health Inc (OPK)?
Revenue at Opko Health Inc is growing 4.3% versus a year earlier (3y avg −15.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Opko Health Inc (OPK)?
Earnings per share at Opko Health Inc are down 12.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Opko Health Inc (OPK) generate?
The free cash flow of Opko Health Inc is −$191M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Opko Health Inc (OPK) carry?
The net debt of Opko Health Inc is $64.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Opko Health Inc in the live analysis

One click puts Opko Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.